TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques

Journal of Immunology

Volumn 175, Issue 4, 2005, Pages 2721-2729

  Gottlieb, Alice B ^a   Chamian, Francesca ^b   Masud, Salman ^a   Cardinale, Irma ^b   Abello, Maria Veronica ^b   Lowes, Michelle A ^b   Chen, Fei ^a   Magliocco, Melissa ^a   Krueger, James G ^b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD83 ANTIGEN; CHEMOKINE; CYTOKERATIN 16; CYTOKINE; ETANERCEPT; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN P 15095; GRANZYME B; GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 19; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; LANOLIN ALCOHOL; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; NITRIC OXIDE SYNTHASE; STAT1 PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CELL INFILTRATION; CELL MATURATION; CELL TYPE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; EPIDERMIS HYPERPLASIA; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; LYMPHOCYTE; NEUTROPHIL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PSORIASIS; SKIN BIOPSY; SKIN INFLAMMATION; T LYMPHOCYTE ACTIVATION;

EID: 23444432216     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.4.2721     Document Type: Article

References (62)

1. Banno, T., A. Gazel, and M. Blumenberg, 2004. Effects of tumor necrosis factor-α (TNFα) in epidermal keratinocytes revealed using global transcriptional profiling. J. Biol. Chem. 279: 32633-32642.
2. Norris, D. A. 1990. Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. J. Invest. Dermalol. 95: 111S-120S.
3. Old, L. J. 1985. Tumor necrosis factor (TNF). Science 230: 630-632.
4. Zhou, A., S. Scoggin, R. Gaynor, and N. S. Williams. 2003. Identification of NFκB-regulated genes induced by TNFα utilizing expression profiling and RNA interference. Oncogene 22: 2054-2064.
5. Mansbridge, J. N., and A. M. Knapp. 1987. Changes in keratinocyte maturation during wound healing. J. Invest. Dermatol. 89: 253-263.
6. Gottlieb, A. B., R. M. Grossman, L. Khandke, D. M. Carter, P. B. Sehgal, S. M. Fu, A. Granelli-Pipemo, M. Rivas, L. Barazani, and J. G. Krueger. 1992. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J. Invest. Dermatol. 98: 302-309.
7. Gottlieb, A. B., B. Lifshitz, S. M. Fu, L. Staiano-Coico, C. Y. Wang, and D. M. Carter. 1986. Expression of HLA-DR molecules by keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J. Exp. Med. 164: 1013-1028.
8. Gottlieb, A. B., and J. G. Krueger. 1990. HLA region genes and immune activation in the pathogenesis of psoriasis. Arch. Dermatol. 126: 1083-1091.
9. Gottlieb, A. B., J. G. Krueger, L. Khandke, R. M. Grossman, J. Krane, and D. M. Carter. 1991. Role of T cell activation in the pathogenesis of psoriasis. Ann. NY Acad. Sci. 636: 377-379.
10. Gottlieb, S. L., P. Gilleaudeau, R. Johnson, L. Estes, T. G. Woodworm, A. B. Gottlieb, and J. G. Krueger. 1995. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1: 442-447.
11. Krueger, J. 2002. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 46: 1-26.
12. Nestle, F., L. Turka, and B. Nickoloff. 1994. Characterization of dermal dendritic cells in psoriasis: autostimulation of T lymphocytes and induction of Th1 type cytokines. J. Clin. Invest. 94: 202-209.
13. Nickoloff, B. J., and C. E. M. Griffiths. 1990. Lymphocyte trafficking in psoriasis: a new perspective emphasizing the dermal dendrocyte with active dermal recruitment mediated via endothelial cells followed by intra-epidermal T-cell activation. J. Invest. Dermatol. 95: 35S-37S.
14. Baker, B. S., A. F. Swain, C. E. M. Griffiths, J. N. Leonard, L. Fry, and H. Valdimarsson. 1985. Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: the effects of PUVA treatment Clin. Exp. Immunol. 61: 526-534.
15. +) cell immunophenotype in psoriasis, atopic dermatitis, and other inflammatory dermatoses. J. Invest. Dermatol. 87: 358-361.
16. Wrone-Smith, T., and B. J. Nickoloff. 1996. Dermal injection of immunocytes induces psoriasis. J. Clin. Invest. 98: 1878-1887.
17. Gilhar, A., M. David, Y. Ullmann, T. Berkutski, and R. S. Kalish. 1997. T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. J. Invest. Dermatol. 109: 283-288.
18. Boyman, O., H. P. Hefti, C. Conrad, B. Nickoloff, M. Suter, and F. Q. Nestle. 2004. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor α. J. Exp. Med. 199: 731-736.
19. Chaudhari, U., P. Romano, L. D. Mulcahy, L. T. Dooley, D. G. Baker, and A. B. Gottlieb. 2001. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357: 1842-1847.
20. Gottlieb, A. B., S. Masud, R. Ramamurthi, A. Abdulshani, P. Romano, U. Chaudhari, L. T. Dooley, A. A. Fasanmade, and C. Wagner. 2003. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J. Am. Acad. Dermatol. 48: 68-75.
21. Gottlieb, A. B. 2003. Clinical research helps elucidate the role of tumor necrosis factor-α (TNF-α) in the pathogenesis of T1 mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes. Lupus 12: 192-194.
22. Gottlieb, A. B., R. T. Matheson, N. Low, G. G. Krueger, S. Kang, B. S. Goffe, A. A. Gaspari, M. Ling, G. D. Weinstein, A. Nayak, K. B. Gordon, and R. Zitnik. 2003. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol. 139: 1627-1632.
23. Gottlieb, A. B. 2004. Etanercept for the treatment of psoriasis and psoriatic arthritis. Dermatol. Ther. 17: 401-408.
24. Leonardi, C. L., J. L. Powers, R. T. Matheson, B. Goffe, R. Zitnik, A. Wang, and A. B. Gottlieb. 2003. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349: 2014-2022.
25. Frederiksson, T., and U. Pettersson. 1978. Severe psoriasis oral therapy with a new retinoid. Dermatologica 157: 238-244.
26. Chamian, F., M. A. Lowes, S.-L. Lin, E. Lee, T. Kijuchi, P. Gilleaudeau, M. Sullivan-Whalen, I. Cardinale, A. Khatcherian, I. Novitskaya, K. M. Wittkowski, and J. G. Krueger. 2005. Alefacept reduces infiltrating T cells, activated dendritic cells and inflammatory genes in psoriasis vulgaris. Proc. Natl. Acad. Soc. USA 102: 2075-2080.
27. Wittkowski, K. M., E. Lee, R. Nussbaum, F. Chamian., and J. G. Krueger. 2004. Combining several ordinal measures in clinical studies. Stat. Med. 23: 1579-1592.
28. Wollenberg, A., M. Wagner, S. Gunther, A. Towarowski, E. Tuma, M. Moderer, S. Rothenfusser, S. Wetzel, S. Endres, and G. Hartmann. 2002. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J. Invest. Dermatol. 119: 1096-1102.
29. Chamian, F., S. Lin, I. Novitskaya, H. Carbonaro, I. Cardinale, T. Kikuchi, P. Gilleaudeau, K. Wittkowski, K. Papp, M. R. Garovoy, W. Dummer, and J. G. Krueger. 2004. Presence of "inflammatory" dendritic cells in psoriasis vulgaris lesions and modulation by efalizumab (anti-CD11a). J. Invest. Dermatol. 122: A41.
30. Gottlieb, A. B., A. D. Luster, D. N. Posnett, and D. M. Carter. 1988. Detection of a γ-interferon-induced protein (IP-10) in psoriatic plaques. J. Exp. Med. 168: 941-948.
31. Grossman, R. M., J. Krueger, D. Yourish, A. Granelli-Pipemo, D. P. Murphy, L. T. May, T. S. Kupper, P. B. Sehgal, and A. B. Gottlieb. 1989. Interleukin-6 (IL-6) is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl. Acad. Sci. USA 86: 6367-6371.
32. Austin, L., M. Ozawa, T. Kikuchi, I. Walters, and J. Krueger. 1999. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and Th1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113: 752-759.
33. Lee, E., W. Trepicchio, J. Oestreicher, D. Pittman, F. Wang, F. Chamian, M. Dhodapkar, and J. G. Krueger. 2004. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199: 125-130.
34. Oestreicher, J. L., I. B Walters, T. Kikuchi, P. Gilleaudeau, J. Surette, U. Schwertschlag, A. J. Domer, J. G. Krueger, and W. L. Trepicchio. 2001. Molecular classification of psoriasis disease-associated genes through pharmacodynamic expression profiling. Pharmacogenomics J. 1: 272-287.
35. Suomela, S., A. L. Kariniemi, E. Snellman, and U. Saarialho-Kere. 2001. Metalloelastase (MMP-12) and 92-kDa gelatinase (MMP-9) as well as their inhibitors, TIMP-1 and -3, are expressed in psoriatic lesions. Exp. Dermatol. 10: 175-183.
36. Lew, W., A. M. Bowcock, and J. G. Krueger. 2004. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "type 1" inflammatory gene expression. Trends Immunol. 25: 295-305.
37. Lew, W., E. Lee, and J. G. Krueger. 2004. Psoriasis genomics: analysis of proinflammatory (type 1) gene expression in large plaque (Western) and small plaque (Asian) psoriasis vulgaris. Br. J. Dermatol. 150: 668-676.
38. Paleolog, E. M., M. Hunt, M. J. Elliott, M. Feldmann, R. N. Maini, and J. N. Woody. 1996. Deactivation of vascular endothelium by monoclonal antitumor necrosis factor-α antibody in rheumatoid arthritis. Arthritis Rheum. 39: 1082-1091.
39. Schuerwegh, A. J., J. F. Van Offel, W. J. Stevens, C. H. Bridts, and L. S. De Clerck. 2003. Influence of therapy with chimeric monoclonal tumour necrosis factor-α antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients. Rheumatology 42: 541-548.
40. Schotte, H., B. Schluter, P. Willeke, E. Mickholz, M. Schorat, V. Domschke, and M. Gaubitz. 2004. Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology 43: 960-964.
41. Catrina, A. I., J. Lampa, S. Emestam, E. af Klint, J. Bratt, L. Klareskog, and A. K. Ulfgren. 2002. Anti-tumour necrosis factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology 41: 484-489.
42. Brennan, F. M., K. A. Browne, P. A. Green, J.-M. Jaspar, R. N. Maini, and M. Feldmann. 1997. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-α (cA2) therapy. Br. J. Rheum. 36: 643-650.
43. Klimiuk, P., S. Sierakowski, I. Domyslawaska, and J. Chwiecko. 2004. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J. Rheumatol. 31: 238-240.
44. Drynda, S., C. Kuhne, and J. Kekow. 2002. Soluble tumour necrosis factor receptor treatment does not affect raised transforming growth factor β levels in rheumatoid arthritis. Ann. Rheum. Dis. 61: 254-256.
45. Tokayer, A., S. Carsons, B. Chokshi, and F. Santiago-Schwarz. 2004. High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: associated with dendritic cell growth activity. J. Rheumatol. 29: 454-461.
46. Agnholt, J., J. F. Dahlerup, and K. Kaltoft. 2003. The effect of etanercept and infliximab on the production of tumour necrosis factor α, interferon-γ and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokines 23: 76-85.
47. Tak, P.-P., P. C. Taylor, F. C. Breedveld, T. Smeets, M. R. Daha, P. M. Kluin, A. E. Meinders, and R. N. Maini. 1996. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 39: 1077-1081.
48. Canete, J. D., J. L. Pablos, R. Sanmarti, C. Mallofre, S. Marsal, J. Maymo, J. Gratacos, J. Mezquita, C. Mezquita, and M. C. Cid. 2004. Antiangiogenic effects of anti-tumor necrosis factor α therapy with infliximab in psoriatic arthritis. Arthritis. Rheum. 50: 1636-1641.
49. Zhou, X., J. G. Krueger, M.-C. J. Kao, E. Lee, F. Du, A. Menter, M. D., W. H. Wong, and A. M. Bowcock. 2003. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol. Genomics 13: 69-78.
50. Bogdan, C. 2001. Nitric oxide and the immune response. Nat. Immunol. 2: 907-916.
51. Morhenn, V. B. 1997. Langerhans cells may trigger the psoriatic disease process via production of nitric oxide. Immunol. Today 18: 433-436.
52. van Lieshout, A. W. T., P. Barrerera, R. L. Smeets, G. J. Pesman, P. L. C. M. van Riel, W. B. vanden Berg, and T. R. D. J. Radstake. 2005. Inhibition of TNF-α during maturation of dendritic cells results in the development of semi-mature DC: a potential mechanism for the beneficial effects of TNFα blockade in rheumatoid arthritis. Ann. Rheum. Dis. 64: 408-414.
53. Ritter, U., A. Meissner, J. Ott, and H. Korner. 2003. Analysis of the maturation process of dendritic cells deficient for TNF and lymphotoxin-α reveals an essential role for TNF. J. Leukocyte Biol. 74: 216-222.
54. Abe, K., F. O. Yarovinsky, T. Murakami, A. N. Shakhov, A. V. Tumanov, D. Ito, L. N. Drutskaya, K. Pfeffer, D. V. Kuprash, K. L. Kornschlies, and S. A. Nedospasov. 2003. Distinct contributions of TNF and LT cytokines to the development of dendritic cells in vitro and their recruitment in vivo. Blood 101: 1477-1483.
55. + cells by tumor necrosis factor α. Exp. Hematol. 32: 450-460.
56. Gottlieb, A. B., R. Evans, S. Li, L. T. Dooley, C. Guzzo, A. D. Baker, M. Bala, C. W. Marano, and A. Menter. 2004. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 51: 534-542.
57. Agnholt, J., and K. Kaltoft. 2001. Infliximab downregulates interferon-γ production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokines 15: 212-222.
58. Homey, B., M. Dieu-Nosjean, A. Wiesenbom, C. Massacrier, J. Pin, E. Oldham, D. Catron, M. Buchanan, A. Muller, R. de Waal Malfyt, G. Deng, R. Orozco, T. Ruzicka, P. Lehmann, S. Lebecque, C. Caux, and A. Zlotnik. 2000. Up-regulation of macrophage inflammatory protein-3 α/CCL20 and CC chemokine receptor 6 in psoriasis. J. Immunol. 164: 6621-6632.
59. Barker, J. N., M. L. Jones, R. S. Mitra, E. Crockett-Torabe, J. C. Fantone, S. L. Kunkel, J. S. Warren, V. M. Dixit, and B. J. Nickoloff. 1991. Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am. J. Pathol. 139: 869-876.
60. Rothlein, R., M. Czajkowski, M. M. O'Neill, S. D. Marlin, E. Mainolfi, and V. J. Merluzzi. 1988. Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines: regulation by pharmacologic agents and neutralizing antibodies. J. Immunol. 141: 1665-1669.
61. Singer, K. H., D. T. Tuck, H. A. Sampson, and R. P. Hall. 1989. Epidermal keratinocytes express the adhesion molecule intercellular adhesion molecule-1 in inflammatory dermatoses. J. Invest. Dermatol. 92: 746-750.
62. Pine, R. 1997. Convergence of TNFα and IFNγ signalling pathways through synergistic induction of IRF-1/ISGF-2 is mediated by a composite GAS/κB promoter element. Nucleic Acids Res. 25: 4346-4354.